Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Colon Cancer treatment details. Biologic therapy. Chemotherapy. Rocky Mountain Cancer Center, Denver, CO, United States



Survival: 12.3 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs: Leucovorin
Country: United States
   
City/State/Province: Denver, CO
   
Hospital: Rocky Mountain Cancer Center
   
Journal: Link
   
Date: 3/2013

Description:
Patients:
This phase 2 study involved patients with previously treated metastatic colorectal cancer with the KRAS mutation. These patients were divided into three separate treatment groups. Group A consisted of 51 patients with a median age of 59 years and 53% male. Group B had of 52 patients with a median age of 58 years and 46% male. There were 52 patients in group C with a median age of 59 years and 44% male.


Treatment:
Patients in group A were treated with the chemotherapy combination called FOLFIRI (5-fluorouracil, irinotecan, and leucovorin) and the biologic therapy agent conatumumab (an antibody that binds to the TR-2 protein to induce cell death).

Patients in group B were treated with the chemotherapy combination called FOLFIRI (5-fluorouracil, irinotecan, and leucovorin) and the biologic therapy agent ganitumab (an antibody that binds to the IGF-1R protein to interfere with cancer cell survival).

Patients in group C were treated with the chemotherapy combination called FOLFIRI (5-fluorouracil, irinotecan, and leucovorin) and a placebo.

Toxicities:
There was one treatment-related death due to unknown causes in group A. Grade 3-4 neutropenia, diarrhea, and abdominal pain were also reported.

There was one treatment-related death in group B due to severely high blood sugar. Grade 3-4 neutropenia, intestinal obstruction, and anemia were also reported.

The most severe toxicities were of grade 4 and included grade 3-4 neutropenia, diarrhea, and vomiting.

Results:
The median overall survival for groups A, B, and C was 12.3, 12.4, and 12.0 months, respectively.

Support:
This study was supported by Amgen Inc.

Correspondence: Dr. Allen Cohn; email: allen.cohn@usoncology.com

E-mail to a Friend Email Physician More Information